Sam Casillas
Head of KOL Advocacy Development, Oncology/Rare Disease Marketing & Commercialization at QED Therapeutics - Palo Alto, CA, US
Sam Casillas's Colleagues at QED Therapeutics
Sam Casillas's Contact Details
HQ
650-231-4088
650-231-4088
Location
Pacifica,California,United States
Pacifica,California,United States
Company
QED Therapeutics
QED Therapeutics
Sam Casillas's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Sam Casillas
Sam Casillas currently works for QED Therapeutics.
Sam Casillas's role at QED Therapeutics is Head of KOL Advocacy Development, Oncology/Rare Disease Marketing & Commercialization.
Sam Casillas's email address is ***@qedtx.com. To view Sam Casillas's full email address, please signup to ConnectPlex.
Sam Casillas works in the Research industry.
Sam Casillas's colleagues at QED Therapeutics are Deborah Mortensen, Yvonne Stone, Roshni Khanna, Rocio Reategui, Mehrak Kiankarimi, Daniela Rogoff, Elizabeth Freas and others.
Sam Casillas's phone number is 650-231-4088